Metsera expects its cash will last into 2027. Two other life science companies went public this past week. Here’s a look at those IPOs: Maze Therapeutics Finds Way to $140M IPO for Chronic ...

Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Sionna is working out its IPO plans days after obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics both listed on the Nasdaq with offerings of $275 million and $140 million ...

Metsera's IPO is richest among the Friday debutantes ... of $44.1 million and revenue of $12 million for full-year 2023. Maze Therapeutics Inc. (MAZE) priced 8.75 million shares at $16 a share ...

Obesity biotech Metsera (MTSR) priced its downsized ... Precision medicine biotech Maze Therapeutics (MAZE) priced its upsized IPO at the midpoint to raise $140 million at a $731 million market ...

Aardvark’s IPO comes amid an uptick in biotech ... far in 2025 include obesity drug developer Metsera, Sionna Therapeutics, kidney disease startup Maze Therapeutics, and Ascentage Pharma.

Its prospectus says that the IPO will fund phase 1 and phase ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze Therapeutics, which filed to list on ...

January 31, 2025 Metsera hits $2.7 bln valuation as shares ... January 31, 2025 Biotech firm Maze Therapeutics raises $140 million in US IPO Maze Therapeutics said on Thursday that it raised ...

Aardvark’s IPO comes amid an uptick in biotech public offerings since the start of the year. Other companies that have gone public so far in 2025 include obesity drug developer Metsera, Sionna ...